Anixa Historical Cash Flow

ANIX Stock

USD 3.30 0.01 0.30%

Analysis of Anixa Biosciences cash flow over time is an excellent tool to project Anixa Biosciences future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Other Cashflows From Financing Activities of 441.9 K or Depreciation of 50.3 K as it is a great indicator of Anixa Biosciences ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Anixa Biosciences latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Anixa Biosciences is a good buy for the upcoming year.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.

About Anixa Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Anixa balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Anixa's non-liquid assets can be easily converted into cash.

Anixa Biosciences Cash Flow Chart

At this time, Anixa Biosciences' Begin Period Cash Flow is fairly stable compared to the past year. Other Cashflows From Financing Activities is likely to rise to about 441.9 K in 2024, despite the fact that Change In Cash is likely to grow to (9.8 M).

Change In Cash Free Cash Flow Begin Period Cash Flow Other Cashflows From Financing Activities Depreciation End Period Cash Flow

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Depreciation

Depreciation indicates how much of Anixa Biosciences value has been used up. For tax purposes Anixa Biosciences can deduct the cost of the tangible assets it purchases as business expenses. However, Anixa Biosciences must depreciate these assets in accordance with IRS rules about how and when the deduction may be taken, and how long it will last. The systematic allocation of the cost of a tangible asset over its useful life.

Most accounts from Anixa Biosciences' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Anixa Biosciences current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.At this time, Anixa Biosciences' Begin Period Cash Flow is fairly stable compared to the past year. Other Cashflows From Financing Activities is likely to rise to about 441.9 K in 2024, despite the fact that Change In Cash is likely to grow to (9.8 M).

Anixa Biosciences cash flow statement Correlations

	Change In Cash	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Net Income	End Period Cash Flow	Change To Inventory	Change To Liabilities	Change To Account Receivables	Stock Based Compensation	Sale Purchase Of Stock	Investments	Cash And Cash Equivalents Changes	Cash Flows Other Operating	Change To Netincome	Change Receivables	Net Borrowings	Change To Operating Activities	Issuance Of Capital Stock
Change In Cash		0.29	0.15	-0.64	0.17	-0.13	0.02	0.6	-0.1	-0.5	0.25	0.11	0.14	0.45	0.31	0.03	-0.05	-0.03	0.13	-0.26	0.85
Free Cash Flow	0.29		0.26	-0.57	0.31	-0.23	0.74	-0.2	-0.35	-0.62	0.45	-0.36	-0.31	0.49	0.58	-0.09	-0.54	0.01	0.44	-0.29	-0.11
Change In Working Capital	0.15	0.26		-0.16	0.13	-0.82	0.26	0.06	-0.88	0.23	0.17	0.2	0.15	0.02	0.22	-0.09	-0.39	-0.22	0.26	0.21	0.05
Begin Period Cash Flow	-0.64	-0.57	-0.16		-0.47	0.14	-0.41	0.21	0.19	0.48	-0.23	0.31	-0.18	-0.88	-0.81	0.04	0.51	0.09	-0.44	0.19	-0.18
Depreciation	0.17	0.31	0.13	-0.47		0.26	-0.03	-0.25	0.2	-0.07	0.07	-0.11	-0.1	0.47	0.53	-0.07	-0.17	0.05	0.24	-0.05	-0.13
Other Non Cash Items	-0.13	-0.23	-0.82	0.14	0.26		-0.42	-0.02	0.93	-0.16	-0.17	-0.16	-0.17	0.04	-0.09	-0.07	0.37	0.05	-0.04	-0.1	-0.06
Net Income	0.02	0.74	0.26	-0.41	-0.03	-0.42		-0.41	-0.48	-0.34	0.47	-0.71	-0.22	0.35	0.41	-0.33	-0.8	-0.01	0.29	-0.23	-0.29
End Period Cash Flow	0.6	-0.2	0.06	0.21	-0.25	-0.02	-0.41		0.04	-0.16	0.12	0.45	-0.01	-0.33	-0.41	0.09	0.45	0.07	-0.28	-0.17	0.89
Change To Inventory	-0.1	-0.35	-0.88	0.19	0.2	0.93	-0.48	0.04		-0.06	-0.27	-0.11	-0.24	-0.06	-0.2	0.02	0.45	0.17	-0.22	-0.08	0.0
Change To Liabilities	-0.5	-0.62	0.23	0.48	-0.07	-0.16	-0.34	-0.16	-0.06		-0.5	0.28	-0.09	-0.43	-0.52	-0.25	0.14	-0.17	-0.15	0.66	-0.25
Change To Account Receivables	0.25	0.45	0.17	-0.23	0.07	-0.17	0.47	0.12	-0.27	-0.5		-0.29	0.23	0.25	0.39	0.09	-0.46	0.5	-0.26	-0.64	0.14
Stock Based Compensation	0.11	-0.36	0.2	0.31	-0.11	-0.16	-0.71	0.45	-0.11	0.28	-0.29		0.24	-0.31	-0.39	0.45	0.72	0.08	-0.28	0.16	0.35
Sale Purchase Of Stock	0.14	-0.31	0.15	-0.18	-0.1	-0.17	-0.22	-0.01	-0.24	-0.09	0.23	0.24		0.24	0.33	0.24	0.01	0.05	-0.17	-0.26	0.16
Investments	0.45	0.49	0.02	-0.88	0.47	0.04	0.35	-0.33	-0.06	-0.43	0.25	-0.31	0.24		0.79	-0.01	-0.52	0.11	0.24	-0.37	0.03
Cash And Cash Equivalents Changes	0.31	0.58	0.22	-0.81	0.53	-0.09	0.41	-0.41	-0.2	-0.52	0.39	-0.39	0.33	0.79		0.07	-0.62	0.0	0.41	-0.29	-0.18
Cash Flows Other Operating	0.03	-0.09	-0.09	0.04	-0.07	-0.07	-0.33	0.09	0.02	-0.25	0.09	0.45	0.24	-0.01	0.07		0.33	0.61	-0.47	-0.32	0.03
Change To Netincome	-0.05	-0.54	-0.39	0.51	-0.17	0.37	-0.8	0.45	0.45	0.14	-0.46	0.72	0.01	-0.52	-0.62	0.33		0.02	-0.3	0.12	0.3
Change Receivables	-0.03	0.01	-0.22	0.09	0.05	0.05	-0.01	0.07	0.17	-0.17	0.5	0.08	0.05	0.11	0.0	0.61	0.02		-0.85	-0.68	0.01
Net Borrowings	0.13	0.44	0.26	-0.44	0.24	-0.04	0.29	-0.28	-0.22	-0.15	-0.26	-0.28	-0.17	0.24	0.41	-0.47	-0.3	-0.85		0.51	-0.17
Change To Operating Activities	-0.26	-0.29	0.21	0.19	-0.05	-0.1	-0.23	-0.17	-0.08	0.66	-0.64	0.16	-0.26	-0.37	-0.29	-0.32	0.12	-0.68	0.51		-0.21
Issuance Of Capital Stock	0.85	-0.11	0.05	-0.18	-0.13	-0.06	-0.29	0.89	0.0	-0.25	0.14	0.35	0.16	0.03	-0.18	0.03	0.3	0.01	-0.17	-0.21

Click cells to compare fundamentals

Anixa Biosciences Account Relationship Matchups

Anixa Biosciences cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Change In Cash	2.9M	22.7M	(16.8M)	(11.4M)	(10.3M)	(9.8M)
Free Cash Flow	(6.2M)	(4.9M)	(6.5M)	(6.2M)	(5.6M)	(5.3M)
Change In Working Capital	(459.0K)	78.5K	485K	(1.1M)	(954K)	(906.3K)
Begin Period Cash Flow	3.5M	6.4M	29.1M	12.4M	14.2M	14.9M
Other Cashflows From Financing Activities	140.7K	439.8K	452K	366K	420.9K	441.9K
Depreciation	90.2K	59.9K	42K	46K	52.9K	50.3K
Other Non Cash Items	148.1K	(5.4K)	752K	313K	360.0K	549.7K
Total Cash From Operating Activities	(6.2M)	(4.9M)	(6.5M)	(6.2M)	(5.6M)	(5.3M)
Net Income	(10.1M)	(13.1M)	(13.8M)	(9.9M)	(8.9M)	(9.4M)
Total Cash From Financing Activities	9.4M	31.6M	452K	366K	420.9K	399.9K
End Period Cash Flow	6.4M	29.1M	12.4M	915K	1.1M	999.6K
Change To Inventory	(271.7K)	(64.3K)	29K	224K	257.6K	270.5K
Total Cashflows From Investing Activities	(525.5K)	(305.8K)	(3.9M)	(10.7M)	(9.7M)	(9.2M)
Change To Liabilities	216.2K	(347.9K)	(96.2K)	760K	684K	718.2K
Change To Account Receivables	271.7K	64.3K	(29K)	(224K)	(201.6K)	(191.5K)
Stock Based Compensation	3.9M	7.5M	6M	4.4M	5.1M	4.3M
Sale Purchase Of Stock	2.5M	5.7M	9.4M	452K	519.8K	493.8K
Investments	(290K)	(4.0M)	(10.7M)	(5.6M)	(5.0M)	(4.8M)
Cash And Cash Equivalents Changes	(283.5K)	435.7K	2.9M	(16.8M)	(15.1M)	(14.3M)
Cash Flows Other Operating	2.9M	2.1M	24.6K	(136K)	(156.4K)	(148.6K)
Change To Netincome	4.0M	4.1M	7.9M	6.7M	7.7M	3.9M
Change To Operating Activities	202.9K	(169.9K)	174.7K	356K	409.4K	429.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Anixa Stock Analysis

When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Anixa Historical Cash Flow

About Anixa Cash Flow Analysis

Anixa Biosciences Cash Flow Chart

Free Cash Flow

Begin Period Cash Flow

Depreciation

Anixa Biosciences cash flow statement Correlations

Anixa Biosciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Anixa Biosciences cash flow statement Accounts

Also Currently Popular

Additional Tools for Anixa Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Change To Inventory	+ 0.93	Other Non Cash Items
Issuance Of Capital Stock	+ 0.89	End Period Cash Flow
Issuance Of Capital Stock	+ 0.85	Change In Cash
Cash And Cash Equivalents Changes	+ 0.79	Investments
Net Income	+ 0.74	Free Cash Flow
Change To Netincome	+ 0.72	Stock Based Compensation

Investments	- 0.88	Begin Period Cash Flow
Change To Inventory	- 0.88	Change In Working Capital
Net Borrowings	- 0.85	Change Receivables
Other Non Cash Items	- 0.82	Change In Working Capital
Cash And Cash Equivalents Changes	- 0.81	Begin Period Cash Flow
Change To Netincome	- 0.8	Net Income